One hundred ninety eight of the 218 (91%) patients with breast cancer were ER-positive, 36 (16.5%) were human epidermal growth factor receptor 2 (HER2)-positive, and 10 (4.5%) had triple-negative breast cancer (TNBC). This evidence concerns the gene ESR1 and triple-negative breast carcinoma.